# Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

> **NCT04667143** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 760 (estimated)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** Retagliptin, Henagliflozein, metformin XR

## Key facts

- **NCT ID:** NCT04667143
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01
- **Primary completion:** 2022-09
- **Final completion:** 2022-10
- **Target enrollment:** 760 (ESTIMATED)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04667143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04667143, "Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04667143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*